查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1968612

生物製藥市場分析及預測（至2035年）：依類型、產品類型、服務、技術、應用、最終用戶、製程、設備、材料類型及部署模式分類

Biologics Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Application, End User, Process, Device, Material Type, Deployment
出版日期: | 出版商: Global Insight Services | 英文 393 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

預計生物製劑市場規模將從2024年的5.815億美元成長到2034年的13.232億美元，複合年成長率約為8.6%。生物製劑市場涵蓋生物來源的治療產品，例如蛋白質、核酸和細胞。這些生物製劑在治療癌症和自體免疫疾病等慢性疾病方面至關重要。生物技術的進步、慢性疾病的增加以及對個人化醫療日益成長的需求是推動該市場成長的主要因素。單株抗體、基因療法和生物相似藥的創新正在拓展治療選擇並提高療效。監管支持和策略合作進一步推動了市場成長，使生物製藥成為現代療法的基礎。

生物製劑市場正經歷強勁擴張，主要得益於生技和個人化醫療的進步。單株抗體領域憑藉其在治療慢性疾病和癌症方面的顯著療效，已成為成長最快的細分市場。重組蛋白緊隨其後，反映出其在治療和疫苗領域應用範圍的不斷擴大。基因療法由於基因工程和標靶治療的創新而展現出巨大的潛力。細胞療法領域也正蓬勃發展，幹細胞研究也取得了令人矚目的治療成果。生物相似藥的重要性日益凸顯，這主要源自於市場對品牌生物製劑經濟實惠替代方案的需求。這一趨勢正推動醫療保健解決方案朝更易獲取的方向發展。此外，市場對能夠提高生物製藥療法療效和患者依從性的先進藥物遞送系統的需求也在激增。生物製藥公司之間的策略聯盟與合作正在促進創新，加速新型生物製劑的研發，從而為市場持續成長和盈利機會奠定基礎。

市場區隔
類型 單株抗體、疫苗、重組蛋白、基因治療、細胞治療、生物相似藥、血液製品、酶
產品 治療性蛋白質、抗體藥物複合體、細胞激素、融合蛋白、生長因子、荷爾蒙、干擾素、白細胞介素
服務 合約研究、契約製造、臨床試驗、法規事務、品質保證、供應鏈管理、物流
科技 DNA定序、CRISPR、合成生物學、生物加工、奈米技術、蛋白質工程、生物列印
應用領域 腫瘤科、感染疾病、自體免疫疾病科、心血管疾病科、代謝性疾病科、神經科、眼科、皮膚科
最終用戶 製藥公司、生技公司、研究機構、醫院、診所、診斷檢查室、學術機構
過程 上游工程、下游製程、配方、純化、發酵、細胞培養
裝置 生物反應器、離心機、層析法系統、過濾系統、混合系統
材料類型 蛋白質、抗體、核酸、細胞、病毒載體
實施表格 內部開發、外包、混合模式

市場概況：

生物製藥在醫藥市場中持續佔據主導地位，創新療法和成熟治療方法均佔了相當大的市場佔有率。定價策略因生產流程的複雜程度和臨床療效而異。頻繁的新治療方法上市反映了生物技術的進步以及單株抗體、疫苗和基因療法等一系列產品的強勁研發管線。對個人化醫療和標靶治療的需求不斷成長，正在推動市場發展。北美和歐洲是領先的市場，而亞太地區的成長則因醫療保健投資的增加和政府政策的支持而加速。生物製劑市場競爭異常激烈，主要企業都在大力投資研發以維持其競爭優勢。監管至關重要，嚴格的核准流程會影響產品的市場准入和擴張。美國食品藥物管理局管理局 (FDA) 和歐洲藥品管理局 (EMA) 對安全性和有效性設定了高標準，這可能會延遲產品上市，但最終有助於增強市場信心。新興市場蘊藏著盈利的機遇，但駕馭複雜的監管環境需要戰略眼光。生物製劑的未來前景光明，細胞和基因療法的進步正在推動創新和市場發展。

主要趨勢和促進因素：

生物製劑市場正經歷強勁成長，這主要得益於生物技術的進步和對個人化醫療日益成長的需求。單株抗體、細胞療法和基因療法的興起是關鍵趨勢，它們正在改變多種疾病的治療模式。這些創新源自於對疾病機制和人類基因組的深刻理解。監管支持和加速核准流程進一步推動了市場擴張。世界各國政府都認知到生物製劑在滿足未被滿足的醫療需求方面的潛力，並致力於簡化核准流程。此外，慢性病發病率的上升和人口老化也是推動市場發展的關鍵因素，促使人們尋求新的治療方案。生物製藥產業在研發方面也投入了大規模資金。各公司正致力於擴大產能和改善藥物輸送系統。新興市場醫療基礎設施的不斷完善為市場提供了許多機會。策略聯盟和夥伴關係關係日益普遍，使企業能夠利用互補優勢並拓展全球企業發展。在持續創新和策略性措施的推動下，生物製藥市場預計將保持持續成長。

限制與挑戰：

生物製藥市場目前面臨許多重大限制與挑戰。其中一個主要挑戰是生物製藥的高成本，這不僅限制了病患的用藥途徑，也給醫療系統帶來了沉重的經濟負擔。生物製藥生產流程的複雜性進一步加劇了這個問題，需要對專業設施和熟練人員進行大量投資。此外，監管障礙也是一大挑戰。生物製藥嚴格的核准流程導致研發週期延長、成本增加，阻礙了中小企業進入市場。智慧財產權問題同樣構成重大障礙，專利到期生物相似藥的湧入加劇了競爭，並影響了市場佔有率。地緣政治緊張局勢或全球衛生危機導致的供應鏈中斷可能造成生物製藥供不應求和分銷延遲。最後，低溫運輸物流的需求也增加了複雜性和成本，阻礙了市場擴張，尤其是在資源匱乏的地區。

目錄

第1章執行摘要

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制
  • 複合年均成長率：成長分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章 細分市場分析

  • 市場規模及預測：依類型
    • 單株抗體
    • 疫苗
    • 重組蛋白
    • 基因治療
    • 細胞療法
    • 生物相似藥
    • 血液製品
    • 酵素
  • 市場規模及預測：依產品分類
    • 治療性蛋白質
    • 抗體藥物複合體
    • 細胞激素
    • 融合蛋白
    • 生長因子
    • 荷爾蒙
    • 干擾素
    • 白細胞介素
  • 市場規模及預測：依服務分類
    • 委託研究
    • 契約製造
    • 臨床試驗
    • 監管服務
    • 品質保證
    • 供應鏈管理
    • 後勤
  • 市場規模及預測：依技術分類
    • DNA定序
    • CRISPR
    • 合成生物學
    • 生物製程
    • 奈米科技
    • 蛋白質工程
    • 生物列印
  • 市場規模及預測：依應用領域分類
    • 腫瘤學
    • 感染疾病
    • 自體免疫疾病
    • 心血管疾病
    • 代謝性疾病
    • 神經病學
    • 眼科
    • 皮膚科
  • 市場規模及預測：依最終用戶分類
    • 製藥公司
    • 生技公司
    • 研究所
    • 醫院
    • 診所
    • 診斷檢查室
    • 學術機構
  • 市場規模及預測：依製程分類
    • 上游工程
    • 下游工藝
    • 配方
    • 純化
    • 發酵
    • 細胞培養
  • 市場規模及預測：依設備分類
    • 生物反應器
    • 離心機
    • 層析法系統
    • 過濾系統
    • 混合系統
  • 市場規模及預測：依材料類型分類
    • 蛋白質
    • 抗體
    • 核酸
    • 細胞
    • 病毒載體
  • 市場規模及預測：依發展狀況
    • 內部
    • 外包
    • 混合

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地區
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲地區

第6章 市場策略

  • 需求與供給差距分析
  • 貿易和物流限制
  • 價格、成本和利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 法規概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 主要企業的策略

第8章 公司簡介

  • Sandoz
  • Samsung Biologics
  • Biocon
  • Catalent
  • WuXi Biologics
  • Lonza
  • Sartorius
  • Boehringer Ingelheim
  • Fujifilm Diosynth Biotechnologies
  • Abzena
  • AGC Biologics
  • Samsung Bioepis
  • Cytiva
  • Bavarian Nordic
  • MorphoSys

第9章：關於我們

簡介目錄
Product Code: GIS33678

Biologics Market is anticipated to expand from $581.5 million in 2024 to $1,323.2 million by 2034, growing at a CAGR of approximately 8.6%. The Biologics Market encompasses therapeutic products derived from living organisms, including proteins, nucleic acids, and cells. These biologics are pivotal in treating chronic diseases such as cancer and autoimmune disorders. The market is driven by advancements in biotechnology, increasing prevalence of chronic diseases, and rising demand for personalized medicine. Innovations in monoclonal antibodies, gene therapies, and biosimilars are expanding treatment options and enhancing efficacy. Regulatory support and strategic collaborations further propel market growth, positioning biologics as a cornerstone of modern therapeutics.

The Biologics Market is experiencing robust expansion, driven by advancements in biotechnology and personalized medicine. The monoclonal antibodies segment emerges as the top-performing sub-segment, owing to their efficacy in treating chronic diseases and cancer. Recombinant proteins follow closely, reflecting increased applications in therapeutic treatments and vaccines. Gene therapy showcases significant potential, propelled by innovations in genetic engineering and targeted treatments. The cell therapy sub-segment is gaining momentum, with stem cell research offering promising therapeutic outcomes. Biosimilars are becoming increasingly relevant, driven by the need for cost-effective alternatives to branded biologics. This trend is prompting a shift towards more accessible healthcare solutions. The market is also witnessing a surge in demand for advanced drug delivery systems, enhancing the efficacy and patient compliance of biologic treatments. Strategic partnerships and collaborations between biopharmaceutical companies are fostering innovation and accelerating the development of novel biologics, positioning the market for sustained growth and lucrative opportunities.

Market Segmentation
TypeMonoclonal Antibodies, Vaccines, Recombinant Proteins, Gene Therapy, Cell Therapy, Biosimilars, Blood Products, Enzymes
ProductTherapeutic Proteins, Antibody Drug Conjugates, Cytokines, Fusion Proteins, Growth Factors, Hormones, Interferons, Interleukins
ServicesContract Research, Contract Manufacturing, Clinical Trials, Regulatory Services, Quality Assurance, Supply Chain Management, Logistics
TechnologyDNA Sequencing, CRISPR, Synthetic Biology, Bioprocessing, Nanotechnology, Protein Engineering, Bioprinting
ApplicationOncology, Infectious Diseases, Autoimmune Diseases, Cardiovascular Diseases, Metabolic Disorders, Neurology, Ophthalmology, Dermatology
End UserPharmaceutical Companies, Biotechnology Companies, Research Institutes, Hospitals, Clinics, Diagnostic Labs, Academic Institutions
ProcessUpstream Processing, Downstream Processing, Formulation, Purification, Fermentation, Cell Culture
DeviceBioreactors, Centrifuges, Chromatography Systems, Filtration Systems, Mixing Systems
Material TypeProteins, Antibodies, Nucleic Acids, Cells, Viral Vectors
DeploymentIn-house, Outsourced, Hybrid

Market Snapshot:

Biologics continue to dominate the pharmaceutical landscape, with significant market share held by innovative therapies and established treatments. Pricing strategies vary, driven by the complexity of production and clinical efficacy. New product launches are frequent, reflecting advancements in biotechnology and a robust pipeline of monoclonal antibodies, vaccines, and gene therapies. The market is buoyed by increasing demand for personalized medicine and targeted therapies. North America and Europe are key regions, though Asia-Pacific is witnessing accelerated growth due to rising healthcare investments and supportive government policies. Competition in the biologics market is intense, with leading companies investing heavily in R&D to maintain their competitive edge. Regulatory influences play a pivotal role, with stringent approval processes impacting market entry and expansion. The FDA and EMA set high standards, ensuring safety and efficacy, which can delay product launches but ultimately enhance market credibility. Emerging markets offer lucrative opportunities, yet navigating diverse regulatory landscapes requires strategic acumen. Biologics' future is promising, with advancements in cell and gene therapies driving innovation and market evolution.

Geographical Overview:

The biologics market is witnessing robust growth across diverse regions, each presenting unique opportunities. North America retains a dominant position, bolstered by advanced healthcare infrastructure and significant R&D investments. The presence of leading biopharmaceutical firms further drives innovation and market expansion. Europe follows, with its strong emphasis on biotechnology research and favorable regulatory frameworks enhancing market dynamics. The Asia Pacific region is experiencing rapid market growth, driven by an increasing prevalence of chronic diseases and rising healthcare expenditure. Countries like China and India are emerging as lucrative markets due to their large patient populations and government support for biotechnology. Latin America presents promising growth prospects, with Brazil and Mexico investing in healthcare advancements. The Middle East & Africa region is gradually gaining traction, with countries like the UAE and South Africa recognizing the potential of biologics in improving healthcare outcomes. These emerging markets offer significant opportunities for expansion and investment in the biologics sector.

Key Trends and Drivers:

The biologics market is experiencing robust growth, fueled by advancements in biotechnology and increased demand for personalized medicine. Key trends include the rise of monoclonal antibodies and cell and gene therapies, which are revolutionizing treatment paradigms across various diseases. These innovations are driven by a deeper understanding of disease mechanisms and the human genome. Regulatory support and expedited approval pathways are further accelerating market expansion. Governments are recognizing the potential of biologics to address unmet medical needs, thus streamlining approval processes. Additionally, the increasing prevalence of chronic diseases and aging populations are significant drivers, necessitating novel therapeutic solutions. The biopharmaceutical industry is also witnessing substantial investments in research and development. Companies are focusing on enhancing production capabilities and improving drug delivery systems. Opportunities abound in emerging markets, where healthcare infrastructure is evolving. Strategic collaborations and partnerships are becoming prevalent, enabling firms to leverage complementary strengths and expand their global footprint. The biologics market is poised for sustained growth, driven by continuous innovation and strategic initiatives.

Restraints and Challenges:

The biologics market is currently encountering several significant restraints and challenges. One of the primary challenges is the high cost of biologic drugs, which limits accessibility for patients and places a financial burden on healthcare systems. The complexity of manufacturing processes for biologics further exacerbates this issue, as it requires significant investment in specialized facilities and skilled personnel. Additionally, regulatory hurdles present another formidable challenge. The stringent approval processes for biologics can lead to prolonged timelines and increased costs, discouraging smaller companies from entering the market. Intellectual property concerns also pose a significant barrier, as patent expirations open the door to biosimilars, intensifying competition and impacting market share. Supply chain disruptions, often caused by geopolitical tensions or global health crises, can lead to shortages and delays in the distribution of biologics. Lastly, the need for cold chain logistics adds another layer of complexity and cost, hindering market expansion, particularly in low-resource settings.

Key Players:

Sandoz, Samsung Biologics, Biocon, Catalent, WuXi Biologics, Lonza, Sartorius, Boehringer Ingelheim, Fujifilm Diosynth Biotechnologies, Abzena, AGC Biologics, Samsung Bioepis, Cytiva, Bavarian Nordic, MorphoSys

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by End User
  • 2.7 Key Market Highlights by Process
  • 2.8 Key Market Highlights by Device
  • 2.9 Key Market Highlights by Material Type
  • 2.10 Key Market Highlights by Deployment

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Monoclonal Antibodies
    • 4.1.2 Vaccines
    • 4.1.3 Recombinant Proteins
    • 4.1.4 Gene Therapy
    • 4.1.5 Cell Therapy
    • 4.1.6 Biosimilars
    • 4.1.7 Blood Products
    • 4.1.8 Enzymes
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Therapeutic Proteins
    • 4.2.2 Antibody Drug Conjugates
    • 4.2.3 Cytokines
    • 4.2.4 Fusion Proteins
    • 4.2.5 Growth Factors
    • 4.2.6 Hormones
    • 4.2.7 Interferons
    • 4.2.8 Interleukins
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Contract Research
    • 4.3.2 Contract Manufacturing
    • 4.3.3 Clinical Trials
    • 4.3.4 Regulatory Services
    • 4.3.5 Quality Assurance
    • 4.3.6 Supply Chain Management
    • 4.3.7 Logistics
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 DNA Sequencing
    • 4.4.2 CRISPR
    • 4.4.3 Synthetic Biology
    • 4.4.4 Bioprocessing
    • 4.4.5 Nanotechnology
    • 4.4.6 Protein Engineering
    • 4.4.7 Bioprinting
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Oncology
    • 4.5.2 Infectious Diseases
    • 4.5.3 Autoimmune Diseases
    • 4.5.4 Cardiovascular Diseases
    • 4.5.5 Metabolic Disorders
    • 4.5.6 Neurology
    • 4.5.7 Ophthalmology
    • 4.5.8 Dermatology
  • 4.6 Market Size & Forecast by End User (2020-2035)
    • 4.6.1 Pharmaceutical Companies
    • 4.6.2 Biotechnology Companies
    • 4.6.3 Research Institutes
    • 4.6.4 Hospitals
    • 4.6.5 Clinics
    • 4.6.6 Diagnostic Labs
    • 4.6.7 Academic Institutions
  • 4.7 Market Size & Forecast by Process (2020-2035)
    • 4.7.1 Upstream Processing
    • 4.7.2 Downstream Processing
    • 4.7.3 Formulation
    • 4.7.4 Purification
    • 4.7.5 Fermentation
    • 4.7.6 Cell Culture
  • 4.8 Market Size & Forecast by Device (2020-2035)
    • 4.8.1 Bioreactors
    • 4.8.2 Centrifuges
    • 4.8.3 Chromatography Systems
    • 4.8.4 Filtration Systems
    • 4.8.5 Mixing Systems
  • 4.9 Market Size & Forecast by Material Type (2020-2035)
    • 4.9.1 Proteins
    • 4.9.2 Antibodies
    • 4.9.3 Nucleic Acids
    • 4.9.4 Cells
    • 4.9.5 Viral Vectors
  • 4.10 Market Size & Forecast by Deployment (2020-2035)
    • 4.10.1 In-house
    • 4.10.2 Outsourced
    • 4.10.3 Hybrid

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Application
      • 5.2.1.6 End User
      • 5.2.1.7 Process
      • 5.2.1.8 Device
      • 5.2.1.9 Material Type
      • 5.2.1.10 Deployment
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Application
      • 5.2.2.6 End User
      • 5.2.2.7 Process
      • 5.2.2.8 Device
      • 5.2.2.9 Material Type
      • 5.2.2.10 Deployment
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Application
      • 5.2.3.6 End User
      • 5.2.3.7 Process
      • 5.2.3.8 Device
      • 5.2.3.9 Material Type
      • 5.2.3.10 Deployment
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Application
      • 5.3.1.6 End User
      • 5.3.1.7 Process
      • 5.3.1.8 Device
      • 5.3.1.9 Material Type
      • 5.3.1.10 Deployment
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Application
      • 5.3.2.6 End User
      • 5.3.2.7 Process
      • 5.3.2.8 Device
      • 5.3.2.9 Material Type
      • 5.3.2.10 Deployment
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Application
      • 5.3.3.6 End User
      • 5.3.3.7 Process
      • 5.3.3.8 Device
      • 5.3.3.9 Material Type
      • 5.3.3.10 Deployment
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Application
      • 5.4.1.6 End User
      • 5.4.1.7 Process
      • 5.4.1.8 Device
      • 5.4.1.9 Material Type
      • 5.4.1.10 Deployment
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Application
      • 5.4.2.6 End User
      • 5.4.2.7 Process
      • 5.4.2.8 Device
      • 5.4.2.9 Material Type
      • 5.4.2.10 Deployment
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Application
      • 5.4.3.6 End User
      • 5.4.3.7 Process
      • 5.4.3.8 Device
      • 5.4.3.9 Material Type
      • 5.4.3.10 Deployment
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Application
      • 5.4.4.6 End User
      • 5.4.4.7 Process
      • 5.4.4.8 Device
      • 5.4.4.9 Material Type
      • 5.4.4.10 Deployment
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Application
      • 5.4.5.6 End User
      • 5.4.5.7 Process
      • 5.4.5.8 Device
      • 5.4.5.9 Material Type
      • 5.4.5.10 Deployment
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Application
      • 5.4.6.6 End User
      • 5.4.6.7 Process
      • 5.4.6.8 Device
      • 5.4.6.9 Material Type
      • 5.4.6.10 Deployment
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Application
      • 5.4.7.6 End User
      • 5.4.7.7 Process
      • 5.4.7.8 Device
      • 5.4.7.9 Material Type
      • 5.4.7.10 Deployment
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Application
      • 5.5.1.6 End User
      • 5.5.1.7 Process
      • 5.5.1.8 Device
      • 5.5.1.9 Material Type
      • 5.5.1.10 Deployment
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Application
      • 5.5.2.6 End User
      • 5.5.2.7 Process
      • 5.5.2.8 Device
      • 5.5.2.9 Material Type
      • 5.5.2.10 Deployment
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Application
      • 5.5.3.6 End User
      • 5.5.3.7 Process
      • 5.5.3.8 Device
      • 5.5.3.9 Material Type
      • 5.5.3.10 Deployment
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Application
      • 5.5.4.6 End User
      • 5.5.4.7 Process
      • 5.5.4.8 Device
      • 5.5.4.9 Material Type
      • 5.5.4.10 Deployment
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Application
      • 5.5.5.6 End User
      • 5.5.5.7 Process
      • 5.5.5.8 Device
      • 5.5.5.9 Material Type
      • 5.5.5.10 Deployment
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Application
      • 5.5.6.6 End User
      • 5.5.6.7 Process
      • 5.5.6.8 Device
      • 5.5.6.9 Material Type
      • 5.5.6.10 Deployment
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Application
      • 5.6.1.6 End User
      • 5.6.1.7 Process
      • 5.6.1.8 Device
      • 5.6.1.9 Material Type
      • 5.6.1.10 Deployment
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Application
      • 5.6.2.6 End User
      • 5.6.2.7 Process
      • 5.6.2.8 Device
      • 5.6.2.9 Material Type
      • 5.6.2.10 Deployment
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Application
      • 5.6.3.6 End User
      • 5.6.3.7 Process
      • 5.6.3.8 Device
      • 5.6.3.9 Material Type
      • 5.6.3.10 Deployment
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Application
      • 5.6.4.6 End User
      • 5.6.4.7 Process
      • 5.6.4.8 Device
      • 5.6.4.9 Material Type
      • 5.6.4.10 Deployment
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Application
      • 5.6.5.6 End User
      • 5.6.5.7 Process
      • 5.6.5.8 Device
      • 5.6.5.9 Material Type
      • 5.6.5.10 Deployment

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Sandoz
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Samsung Biologics
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Biocon
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Catalent
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 WuXi Biologics
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Lonza
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Sartorius
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Boehringer Ingelheim
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Fujifilm Diosynth Biotechnologies
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Abzena
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 AGC Biologics
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Samsung Bioepis
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Cytiva
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Bavarian Nordic
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 MorphoSys
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us